Oncolytic virus therapy for prostate cancer: Review Article

International Journal of Urology

Volumn 17, Issue 1, 2010, Pages 20-30

  Fukuhara, Hiroshi ^a   Homma, Yukio ^a   Todo, Tomoki ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Gene therapy; Oncolytic; Prostate cancer; Replication competent; Virotherapy; Virus therapy

Indexed keywords

ACICLOVIR; CG 706; CG 7870; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUTAMIDE; G 207; G 47 DELTA; GANCICLOVIR; IMMUNOMODULATING AGENT; JX 963; NV 1023; NV 1042; ONCOLYTIC ADENOVIRUS; ONCOLYTIC NEWCASTLE DISEASE VIRUS; ONCOLYTIC PARAMYXOVIRUS; ONCOLYTIC RESPIRATORY SYNCYTIAL VIRUS; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; PROSTATE SPECIFIC ANTIGEN; PV 701; REOLYSIN; THYMIDINE KINASE; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ADENOVIRUS; CLINICAL TRIAL; DRUG DOSE ESCALATION; ENZYME PRODRUG THERAPY; FLU LIKE SYNDROME; GENE EXPRESSION; HEPATITIS; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNOMODULATION; KIDNEY CANCER; LUNG CANCER; LUNG METASTASIS; MYELOID LEUKEMIA; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; REOVIRUS; REVIEW; SUICIDE GENE THERAPY; THROMBOCYTOPENIA; TRANSGENE; UNSPECIFIED SIDE EFFECT; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRAL GENE THERAPY;

ADENOVIRIDAE; CLINICAL TRIALS AS TOPIC; HERPESVIRUS 1, HUMAN; HUMANS; MALE; ONCOLYTIC VIROTHERAPY; PROSTATIC NEOPLASMS;

EID: 74049123530     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2009.02383.x     Document Type: Review

References (68)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 2009 59 : 225 249.
2. Group PCTC. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000 355 : 1491 1498.
3. Krainer M, Tomek S, Elandt K et al. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer. J. Urol. 2007 177 : 2141 2145 discussion 2145.
4. Kozlowski JM, Ellis WJ, Grayhack JT. Advanced prostatic carcinoma: early versus late endocrine therapy. Urol. Clin. North Am. 1991 18 : 15 24.
5. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat. Med. 2001 7 : 781 787.
6. Harrington KJ, Spitzweg C, Bateman AR, Morris JC, Vile RG. Gene therapy for prostate cancer: current status and future prospects. J. Urol. 2001 166 : 1220 1233.
7. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 1997 3 : 639 645.
8. Stanizzi MA, Hall SJ. Clinical experience with gene therapy for the treatment of prostate cancer. Rev. Urol. 2007 9 Suppl 1 : S20 8.
9. Hardcastle J, Kurozumi K, Chiocca EA, Kaur B. Oncolytic viruses driven by tumor-specific promoters. Curr. Cancer Drug Targets 2007 7 : 181 189.
10. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997 57 : 2559 2563.
11. DeWeese TL, van der Poel H, Li S et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001 61 : 7464 7472.
12. Yu DC, Sakamoto GT, Henderson DR. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 1999 59 : 1498 1504.
13. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 1999 59 : 4200 4203.
14. Small EJ, Carducci MA, Burke JM et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol. Ther. 2006 14 : 107 117.
15. Dilley J, Reddy S, Ko D et al. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther. 2005 12 : 715 722.
16. Irving J, Wang Z, Powell S et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther. 2004 11 : 174 185.
17. Huang P, Watanabe M, Kaku H et al. Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model. Cancer Gene Ther. 2008 15 : 315 322.
18. Ryan PC, Jakubczak JL, Stewart DA et al. Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer. Cancer Gene Ther. 2004 11 : 555 569.
19. Jin F, Xie Z, Kuo CJ, Chung LW, Hsieh CL. Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy. Cancer Gene Ther. 2005 12 : 257 267.
20. Cho WK, Seong YR, Lee YH et al. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. Mol. Ther. 2004 10 : 938 949.
21. Lu Y. Viral based gene therapy for prostate cancer. Curr. Gene Ther. 2001 1 : 183 200.
22. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 1998 9 : 1323 1333.
23. Zhang P, Zeng H, Wei Q et al. Improved effects of a double suicide gene system on prostate cancer cells by targeted regulation of prostate-specific membrane antigen promoter and enhancer. Int. J. Urol. 2008 15 : 442 448.
24. Barton KN, Paielli D, Zhang Y et al. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol. Ther. 2006 13 : 347 356.
25. Sova P, Ren XW, Ni S et al. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol. Ther. 2004 9 : 496 509.
26. Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin. Cancer Res. 2001 7 : 120 126.
27. Thorne SH, Tam BY, Kirn DH, Contag CH, Kuo CJ. Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy. Mol. Ther. 2006 13 : 938 946.
28. Satoh M, Wang H, Ishidoya S et al. Oncolytic virotherapy for prostate cancer by E1A, E1B mutant adenovirus. Urology 2007 70 : 1243 1248.
29. Mantwill K, Kohler-Vargas N, Bernshausen A et al. Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents. Cancer Res. 2006 66 : 7195 7202.
30. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1995 1 : 938 943.
31. Oyama M, Ohigashi T, Hoshi M, Murai M, Uyemura K, Yazaki T. Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207. Jpn J. Cancer Res. 2000 91 : 1339 1344.
32. Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum. Gene Ther. 1999 10 : 2237 2243.
33. Cozzi PJ, Burke PB, Bhargav A et al. Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. Prostate 2002 53 : 95 100.
34. Varghese S, Rabkin SD, Nielsen GP, MacGarvey U, Liu R, Martuza RL. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res. 2007 67 : 9371 9379.
35. Jorgensen TJ, Katz S, Wittmack EK et al. Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia 2001 3 : 451 456.
36. Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl Acad. Sci. USA 2001 98 : 6396 6401.
37. Fukuhara H, Martuza RL, Rabkin SD, Ito Y, Todo T. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin. Cancer Res. 2005 11 : 7886 7890.
38. Fu X, Tao L, Jin A, Vile R, Brenner MK, Zhang X. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol. Ther. 2003 7 : 748 754.
39. Nakamori M, Fu X, Pettaway CA, Zhang X. Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Prostate 2004 60 : 53 60.
40. Lee CY, Bu LX, Rennie PS, Jia WW. An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells. Cancer Gene Ther. 2007 14 : 652 660.
41. Fukuhara H, Todo T. Oncolytic herpes simplex virus type 1 and host immune responses. Curr. Cancer Drug Targets 2007 7 : 181 189.
42. Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RL. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther. 2006 13 : 253 265.
43. Varghese S, Rabkin SD, Nielsen PG, Wang W, Martuza RL. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin. Cancer Res. 2006 12 : 2919 2927.
44. Fukuhara H, Ino Y, Kuroda T, Martuza RL, Todo T. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res. 2005 65 : 10663 10668.
45. Norman KL, Lee PWK. Reovirus as apotential Anticancer therapeutic. In : Hernaiz Driever P, Rabkin SD (eds). Replication-Copetent Viruses for Cancer Therapy, Vol Karger, Basel, 2001 81 99.
46. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 1998 17 : 3351 3362.
47. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998 282 : 1332 1334.
48. Vidal L, Pandha HS, Yap TA et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin. Cancer Res. 2008 14 : 7127 7137.
49. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 2007 4 : 101 117.
50. Wheelock EF, Dingle JH. Observations on the repeated administration of viruses to a patient with acute leukemia. A preliminary report. N. Engl. J. Med. 1964 271 : 645 651.
51. Aghi M, Martuza RL. Oncolytic viral therapies - the clinical experience. Oncogene 2005 24 : 7802 7816.
52. Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett. 2001 172 : 27 36.
53. Lorence RM, Roberts MS, O'Neil JD et al. Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr. Cancer Drug Targets 2007 7 : 157 167.
54. Moss B. Poxviridae: the viruses and their replication. In : Fields BN, Knipe DM, Howley PM (eds). Fields Virology. Lippincott-Raven, Philadelphia, PA, 1996 2637 2671.
55. Bartlett DL. Vaccinia virus. In : Hernaiz Driever P, Rabkin SD (eds). Replication-Copetent Viruses for Cancer Therapy, Vol Karger, Basel, 2001 130 159.
56. Thorne SH, Hwang TH, O'Gorman WE et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J. Clin. Invest. 2007 117 : 3350 3358.
57. Echchgadda I, Kota S, Dela Cruz I et al. Anticancer oncolytic activity of respiratory syncytial virus. Cancer Gene Ther. 2009 doi:10.1038/cgt.2009.34.
58. Kawaguchi Y, Miyamoto Y, Inoue T, Kaneda Y. Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int. J. Cancer 2009 124 : 2478 2487.
59. Liu C, Hasegawa K, Russell SJ, Sadelain M, Peng KW. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate 2009 69 : 1128 1141.
60. Carey BL, Ahmed M, Puckett S, Lyles DS. Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus. J. Virol. 2008 82 : 12104 12115.
61. Berry LJ, Au GG, Barry RD, Shafren DR. Potent oncolytic activity of human enteroviruses against human prostate cancer. Prostate 2008 68 : 577 587.
62. Paielli DL, Wing MS, Rogulski KR et al. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol. Ther. 2000 1 : 263 274.
63. Varghese S, Newsome JT, Rabkin SD et al. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum. Gene Ther. 2001 12 : 999 1010.
64. Freytag SO, Khil M, Stricker H et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2002 62 : 4968 4976.
65. Freytag SO, Stricker H, Peabody J et al. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol. Ther. 2007 15 : 636 642. (Pubitemid 46306608)
66. Freytag SO, Stricker H, Pegg J et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 2003 63 : 7497 7506.
67. Freytag SO, Movsas B, Aref I et al. Phase I Trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for Prostate cancer. Mol. Ther. 2007 15 : 1016 1023. (Pubitemid 46621661)
68. Stoeckel J, Hay JG. Drug evaluation: reolysin - wild-type reovirus as a cancer therapeutic. Curr. Opin. Mol. Ther. 2006 8 : 249 260.